Format

Send to

Choose Destination
J Altern Complement Med. 2017 Nov;23(11):885-889. doi: 10.1089/acm.2016.0367. Epub 2017 Mar 7.

Safety of Daiobotampito in the Treatment of Acute Diverticulitis of the Colon: A Single-Center, Open-Label, Prospective Trial.

Author information

1
1 Center for Kampo Medicine, Keio University School of Medicine , Tokyo, Japan .
2
2 Department of General Internal Medicine, Tokyo Saiseikai Central Hospital , Tokyo, Japan .
3
3 Department of Internal Medicine, Tokyo Saiseikai Central Hospital , Tokyo, Japan .

Abstract

PURPOSE:

The purpose of this study was to investigate the safety of daiobotampito in the treatment of acute diverticulitis of the colon.

METHODS:

We conducted a single-center, open-label, prospective study. Ten patients who suffered from diverticulitis of the colon were recruited. The patients were treated with fasting, antibacterial agents, and daiobotampito extract for 10 days in or out of hospital. The patients individually recorded their body temperature, grade of abdominal pain, number of times that analgesics were used, and number of stools daily. We checked whether the patients had adverse reactions such as abdominal pain or diarrhea.

RESULTS:

No patients experienced serious adverse reactions. One patient had moderate abdominal pain and diarrhea soon after daiobotampito intake. This patient discontinued daiobotampito on day 4, and the pain and diarrhea quickly resolved. The abdominal pain of this patient was worse 6 days before treatment, and the pain was almost relieved with initial daiobotampito treatment.

CONCLUSIONS:

Daiobotampito is a safe treatment option for early stage, acute diverticulitis.

KEYWORDS:

Kampo medicine; daiobotampito; phase II trial; safety

PMID:
28266866
DOI:
10.1089/acm.2016.0367
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center